Reference : Le ciblage thérapeutique : vers une guerre propre et efficace contre le cancer
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
Human health sciences : Oncology
http://hdl.handle.net/2268/36204
Le ciblage thérapeutique : vers une guerre propre et efficace contre le cancer
English
[fr] Targeted therapy: toward a clean and effective war against cancer
Castronovo, Vincenzo mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire - GIGA-R : Labo de recherche sur les métastases >]
Waltregny, David mailto [Université de Liège - ULg > Département des sciences cliniques > Urologie - GIGA-R : Labo de recherche sur les métastases >]
Detry, Olivier mailto [Université de Liège - ULg > > Chirurgie abdominale- endocrinienne et de transplantation >]
Coimbra Marques, Carla mailto [Université de Liège - ULg > > Chirurgie abdominale- endocrinienne et de transplantation >]
De Roover, Arnaud mailto [Université de Liège - ULg > > Chirurgie abdominale- endocrinienne et de transplantation >]
Honore, Pierre mailto [Université de Liège - ULg > > Chirurgie abdominale- endocrinienne et de transplantation >]
De Pauw, Edwin mailto [Université de Liège - ULg > Département de chimie (sciences) > GIGA-R : Laboratoire de spectrométrie de masse (L.S.M.) >]
Turtoi, Andrei mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases >]
2009
Revue Médicale de Liège
Hopital de Baviere
64
20-23
Yes (verified by ORBi)
International
0370-629X
Liège
Belgique
[en] targeted therapy ; cancer ; biomarker
[en] One promising avenue towards the development of more selective, better anticancer drugs consists in the targeted delivery of bioactive compounds to the tumor environment by means of binding molecules specific for tumor-associated biomarkers. Eligibility of such markers for therapeutic use implies ideally three criteria : (i) accessibility from the bloodstream, (ii) expression at sufficient level and (iii) no (or much lower) expression in normal tissues. Most current discovery strategies (such as biomarker searching into body fluids) provide no clue as to whether proteins of interest are accessible, in human tissues, to suitable high-affinity ligands, such as systemically delivered monoclonal antibodies. Innovative proteomic technologies are able to identify such accessible biomarkers and represent a key step in the clinical development of such target therapies.
Researchers ; Professionals
http://hdl.handle.net/2268/36204
also: http://hdl.handle.net/2268/22737

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Pub#63 Castronovo RMLg 2009.pdfNo commentaryPublisher postprint600.3 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.